<DOC>
	<DOCNO>NCT02245243</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetic profile , safety , tolerability single intravenous ( IV ) dose delafloxacin normal healthy subject subject mild , moderate , severe hepatic impairment .</brief_summary>
	<brief_title>Pharmacokinetics Delafloxacin Subjects With Without Hepatic Impairment</brief_title>
	<detailed_description>pharmacokinetic profile , safety , tolerability single intravenous ( IV ) dose delafloxacin normal healthy subject subject mild , moderate , severe hepatic impairment . AUC0-t , AUC0 inf , Cmax , Tmax , Î»z , t1/2 , MRTinf , CL , CLnr , Vss , Vz</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<criteria>Body mass index ( BMI ) 18.5 40 kg/m2 , inclusive . Able provide write , informed consent initiation study related procedure , able , opinion investigator , comply requirement study . Hepatically Impaired Subjects Only ( Groups A , B , C ) : Has clinical diagnosis cirrhosis classify mild ( Group A ) , moderate ( Group B ) , severe ( Group C ) hepatic impairment define ChildPugh classification system ( Section 7.2 ) . Healthy Subjects Only ( Group D ) : Must good health determine investigator base medical history , clinical laboratory result , vital sign measurement , 12 lead electrocardiogram [ ECG ] result , physical examination finding All Subjects ( Groups A D ) : Has clinically significant abnormality past medical history screen physical examination ( exclude hepatic impairment relate stable medical condition within hepatically impaired population subject ) investigator 's sponsor 's opinion may place subject risk interfere outcome variable study . This include , limited , history current cardiac , renal , neurologic , gastrointestinal , respiratory , hematologic , immunologic disease . History presence abnormal ECG , investigator 's opinion , clinically significant would preclude study participation . Has surgical medical condition ( active chronic ) may interfere drug absorption , distribution , metabolism , excretion study drug , condition may place subject risk ( history cholecystectomy allow ) . Has function liver transplant Has history drug and/or alcohol abuse within 6 month Screening Has history current clinically significant mental disorder antagonistic personality compromise validity inform consent . Has donate blood plasma within 30 day dose , lose 1200 mL blood within 4 month first dose study drug . Has history AIDS subject positive result HIV Screening . Hepatically Impaired Subjects Only ( Groups A , B , C ) : Has clinical exacerbation liver disease within 14 day study drug administration ( eg , abdominal pain , ascites , nausea , vomit , anorexia , fever , worsen laboratory result related hepatic function ) . Has evidence acute viral hepatitis within 1 month Day 1 , clinically demonstrable massive tense ascites , evidence severe acute renal failure , active stage 3 stage 4 encephalopathy . Healthy Subjects Only ( Group D ) : Has positive test result hepatitis B surface antigen hepatitis C virus antibody .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Hepatic Impairment , single dose , intravenous</keyword>
</DOC>